InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

Current share price for ILA : $0.370 0.01 (2.63%)+

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$110 Galidesivir GMP manufacturing commences 2 Oct 2026 9:41AM $0.365 $0.370 risen by 1.37%
$110 Annual General Meeting - Rescheduled Date 30 Sep 2026 11:53AM $0.370 $0.370 fallen by 0%
$110 Pivotal Marburg data secured for Galidesivir FDA pathway 31 Aug 2026 9:01AM $0.440 $0.370 fallen by 15.91%
$110 Appendix 4G and Corporate Governance Statement 26 Aug 2026 3:16PM $0.460 $0.370 fallen by 19.57%
$110 Annual Report to shareholders 26 Aug 2026 3:16PM $0.460 $0.370 fallen by 19.57%
$110 Preliminary Final Report 26 Aug 2026 3:04PM $0.460 $0.370 fallen by 19.57%
$110 Island boosts Galidesivir supply as Ebola surges 21 Aug 2026 8:56AM $0.460 $0.370 fallen by 19.57%
$110 Date of AGM & Closing Date for Director Nominations 13 Aug 2026 9:21AM $0.460 $0.370 fallen by 19.57%
$110 Cleansing Notice 12 Aug 2026 9:35AM $0.470 $0.370 fallen by 21.28%
$110 Application for quotation of securities - ILA 12 Aug 2026 9:32AM $0.470 $0.370 fallen by 21.28%
$110 Investor presentation 7 Aug 2026 8:43AM $0.450 $0.370 fallen by 17.78%
$110 Quarterly Appendix 4C and Activities Report 30 Jul 2026 9:47AM $0.380 $0.370 fallen by 2.63%
$110 Investor Presentation - TechKnow Invest Roadshow 27 Jul 2026 9:23AM $0.400 $0.370 fallen by 7.50%
$110 Notification regarding unquoted securities - ILA 13 Jul 2026 4:29PM $0.480 $0.370 fallen by 22.92%
$110 Notification regarding unquoted securities - ILA 13 Jul 2026 4:27PM $0.480 $0.370 fallen by 22.92%
$110 Notification regarding unquoted securities - ILA 13 Jul 2026 4:21PM $0.480 $0.370 fallen by 22.92%
$110 Notification regarding unquoted securities - ILA 13 Jul 2026 4:21PM $0.480 $0.370 fallen by 22.92%
$110 Texas Biomed SOW accelerates pivotal FDA pathway 13 Jul 2026 9:46AM $0.450 $0.370 fallen by 17.78%
$110 Investor Presentation - Ebola Clinical Program 8 Jul 2026 10:02AM $0.480 $0.370 fallen by 22.92%
$110 Notification of cessation of securities - ILA 8 Jul 2026 9:00AM $0.475 $0.370 fallen by 22.11%
$110 Galidesivir approved for treatment use in in Ebola epidemic 7 Jul 2026 9:02AM $0.375 $0.370 fallen by 1.33%
$110 Trading Halt 3 Jul 2026 12:23PM $0.375 $0.370 fallen by 1.33%
$110 Pause in Trading 3 Jul 2026 12:01PM $0.375 $0.370 fallen by 1.33%
$110 Singapore Patent Expands Island's ISLA 101 Viral Protection 2 Jul 2026 9:38AM $0.375 $0.370 fallen by 1.33%
$110 FDA Grants Orphan Designation for Galidesivir in Marburg 17 Jun 2026 8:54AM $0.355 $0.370 risen by 4.23%

1 - 25 of 454 results

Page 1 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.